Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Amy C PetersonThomas Gajewski

Abstract

Vascular endothelial growth factor (VEGF) expression is prognostic in melanoma, and the activity of VEGF is mediated in part through the receptor tyrosine kinase Flk-1. A Phase II study of SU5416, a preferential inhibitor of Flk-1, was carried out in patients with metastatic melanoma to determine clinical response, tolerability, and changes in tumor vascular perfusion. Patients with documented progressive disease and </=1 prior therapy were eligible. Central nervous system metastases were allowed if stable off medication. SU5416 (145 mg/m(2)) was administered via a central catheter twice weekly for 8 weeks. Premedication with dexamethasone, diphenhydramine, and a H(2) blocker was required because of the Cremophor vehicle. Tumor vascular perfusion was assessed before treatment and during week 8 by dynamic contrast magnetic resonance imaging, and plasma was analyzed for VEGF. Thirty-one patients were enrolled. Two-thirds had received prior therapy, 21 had visceral metastasis, and 14 had an elevated lactate dehydrogenase. Mean absolute lymphocyte counts were decreased (P = 0.002), and glucose levels were increased (P = 0.001) posttherapy, presumably because of steroid premedication. Four vascular adverse events were observed. Of 2...Continue Reading

References

Dec 26, 1995·Biochemical and Biophysical Research Communications·B LiuL W Seymour
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·S ParangiD Hanahan
Jun 17, 1998·International Journal of Cancer. Journal International Du Cancer·T Danielsen, E K Rofstad
Feb 25, 1999·Annals of Surgical Oncology·L T NeitzelM P Malafa
Oct 3, 1999·Journal of Magnetic Resonance Imaging : JMRI·J L Evelhoch
Apr 11, 2002·Virchows Archiv : an International Journal of Pathology·Daniela MassiMarco Santucci
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jocelyn HolashJohn S Rudge

❮ Previous
Next ❯

Citations

Aug 23, 2006·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K RassW Tilgen
May 2, 2008·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K RassW Tilgen
Sep 20, 2006·Investigational New Drugs·Matthew G FuryDavid G Pfister
Sep 6, 2013·Current Oncology Reports·Aaron S Mansfield, Svetomir N Markovic
Oct 12, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Panayiotis A KyzasNiki J Agnantis
Jun 23, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U FasolK Mross
Jun 7, 2007·American Journal of Clinical Oncology·Svetomir N MarkovicEdward T Creagan
Jul 16, 2010·Dermatology Research and Practice·R RiaA Vacca
Jun 10, 2008·Neuro-oncology·Craig P CardenMark A Rosenthal
Jun 1, 2006·Cancer Chemotherapy and Pharmacology·Monica M MitaAmita Patnaik
Jul 16, 2005·Hematology·Soon Thye Lim, Alexandra M Levine
Jun 6, 2009·Expert Review of Anticancer Therapy·Nagashree SeetharamuAnna C Pavlick
Feb 8, 2014·Expert Opinion on Investigational Drugs·Shilpa BhatiaPaul B Fisher
Jun 14, 2008·Expert Opinion on Investigational Drugs·Patricia M Lorusso, Joseph Paul Eder
Sep 1, 2015·International Journal of Oncology·Eun Ho KimJoon Kim
Nov 3, 2009·Clinics in Dermatology·Lucia B JilaveanuHarriet M Kluger
Jan 13, 2009·Cancer Treatment Reviews·I M E DesarW T A van der Graaf
Mar 4, 2008·Experimental Dermatology·Paul LoriganAxel Hauschild
May 3, 2006·Medicinal Research Reviews·Ana R QuesadaMiguel A Medina
Sep 27, 2008·American Journal of Hematology·Francesca EliceFrancesco Rodeghiero
Apr 7, 2009·Experimental Dermatology·Carlo PincelliRiccardo G Borroni
Oct 26, 2012·Pigment Cell & Melanoma Research·Jose L Orgaz, Victoria Sanz-Moreno
Sep 30, 2006·Cancer Treatment Reviews·Paola Queirolo, Mirko Acquati
Dec 27, 2005·International Journal of Radiation Oncology, Biology, Physics·Deborah CitrinKevin Camphausen
Nov 29, 2005·The International Journal of Biochemistry & Cell Biology·Malgorzata MilkiewiczTara L Haas
Nov 23, 2005·Expert Opinion on Therapeutic Targets·Keren Paz, Zhenping Zhu
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas F Gajewski
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemEdward Lin
Feb 23, 2007·Nature·Vanessa Gray-SchopferRichard Marais
Jul 3, 2018·PloS One·Martina Buljac-Samardžić, Marianne van Woerkom
Dec 17, 2009·British Journal of Cancer·N MurukeshG C Jayson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Walter M StadlerEverett E Vokes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
John V HeymachGeorge D Demetri
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Maurizio ZangariFrancis J Giles
© 2022 Meta ULC. All rights reserved